The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease

by Alexia Polissidis, Lilian Petropoulou-Vathi, Modestos Nakos-Bimpos, Hardy J. Rideout
Published 2020-06-01

Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations.

by Katerina Melachroinou, Emmanouela Leandrou, Polytimi-Eleni Valkimadi, Anna Memou, Georgios Hadjigeorgiou, Leonidas Stefanis, Hardy J Rideout
Published 2016-01-01

The WD40 domain is required for LRRK2 neurotoxicity.

by Nathan D Jorgensen, Yong Peng, Cherry C-Y Ho, Hardy J Rideout, Donald Petrey, Peng Liu, William T Dauer
Published 2009-12-01

A motif within the armadillo repeat of Parkinson’s-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway

by Nasia Antoniou, Dimitrios Vlachakis, Anna Memou, Emmanouela Leandrou, Polytimi-Eleni Valkimadi, Katerina Melachroinou, Diane B. Re, Serge Przedborski, William T. Dauer, Leonidas Stefanis, Hardy J. Rideout
Published 2018-02-01

The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s Disease

by Hardy J. Rideout, Marie-Christine Chartier-Harlin, Marie-Christine Chartier-Harlin, Matthew J. Fell, Warren D. Hirst, Sarah Huntwork-Rodriguez, Cheryl E. G. Leyns, Omar S. Mabrouk, Jean-Marc Taymans, Jean-Marc Taymans
Published 2020-08-01